Editas Medicine (EDIT) Stock Forecast & Price Target

Compare

3,512 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

EDIT Analyst Ratings

Hold

5 Buy

5 Hold

2 Sell

Based on 12 analysts giving stock ratings to

Editas

Medicine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

EDIT Stock 12 Month Forecast

Average Price Target

$3.88

▲(15.13% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Editas Medicine in the last 3 months. The average price target is $3.88 with a high forecast of $6.00 and a low forecast of $1.00. The average price target represents a 15.13% change from the last price of $3.37.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","7":"$7","1.75":"$1.75","3.5":"$3.5","5.25":"$5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$6.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$3.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.47,2.741538461538462,3.013076923076923,3.2846153846153845,3.556153846153846,3.827692307692308,4.099230769230769,4.3707692307692305,4.642307692307693,4.913846153846153,5.185384615384615,5.456923076923077,5.728461538461538,{"y":6,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.47,2.578461538461539,2.686923076923077,2.7953846153846156,2.903846153846154,3.0123076923076924,3.120769230769231,3.229230769230769,3.3376923076923077,3.4461538461538463,3.5546153846153845,3.663076923076923,3.7715384615384613,{"y":3.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,2.47,2.356923076923077,2.243846153846154,2.1307692307692307,2.017692307692308,1.9046153846153846,1.7915384615384617,1.6784615384615384,1.5653846153846156,1.4523076923076923,1.3392307692307692,1.2261538461538461,1.113076923076923,{"y":1,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.14,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.74,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.27,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.91,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.19,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.27,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.92,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.62,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.77,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.25,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.44,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.47,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$6.00

Average Price Target$3.88

Lowest Price Target$1.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Mitchell Kapoor

H.C. Wainwright

$3→$5

Buy

48.37%

Upside

Reiterated

09/05/25

Analysts Have Conflicting Sentiments on These Healthcare Companies: Novan (NASDAQ: NOVN) and Editas Medicine (NASDAQ: EDIT)After incorporating the HeFH opportunity (with a 15% probability of approval) into our model and after removing SCD/TDT, we reiterate our Buy rating and 12‐month price target of $5.

Joon Lee

Truist Financial

―

Hold

―

Reiterated

09/03/25

Truist Financial Sticks to Their Hold Rating for Editas Medicine (EDIT)

Yanan Zhu

Wells Fargo

$3→$4

Hold

18.69%

Upside

Reiterated

09/03/25

Editas Medicine price target raised to $4 from $3 at Wells FargoEditas Medicine price target raised to $4 from $3 at Wells Fargo

Brian Cheng

J.P. Morgan

―

Sell

―

Reiterated

09/03/25

J.P. Morgan Keeps Their Sell Rating on Editas Medicine (EDIT)

Alec Stranahan

Bank of America Securities

Sell

-70.33%

Downside

Reiterated

09/02/25

Soumit Roy

JonesTrading

―

Hold

―

Reiterated

09/02/25

Editas Medicine (EDIT) Receives a Hold from JonesTradingWe expect new details regarding the nomination of a candidate for the HSC program later this year, but are looking forward to seeing more preclinical data from the CVD program at a later time. Given that the company is still more than Symbol EDIT Price (Sep 1, 2025) 2.57 Market Cap (MM) 231 Dividend NA Enterprise Value (MM) 74 Shares/Units Outstanding (MM) 89.92 Dividend Yield NA Free Float (MM) 89.2 Free Float % 99.2% 52-Week Range 0.91—4.12 3-Month Avg. Daily Vol. 2,454,617 Short Interest (% of Float) NA Total Assets (MM) 211 Est. FY Cash & Cash Eq.

Jonathan Miller

Evercore ISI

$5→$4

Buy

18.69%

Upside

Initiated

08/22/25

Analysts Are Bullish on These Healthcare Stocks: Editas Medicine (EDIT), Tilray (TLRY)

Gena Wang

Barclays

Hold

-10.98%

Downside

Reiterated

08/13/25

Barclays Sticks to Its Hold Rating for Editas Medicine (EDIT)

Jack Allen

Robert W. Baird

$4→$6

Buy

78.04%

Upside

Reiterated

08/13/25

Editas Medicine price target raised to $6 from $4 at BairdEditas Medicine price target raised to $6 from $4 at Baird

Unknown Analyst

Clear Street

Not Ranked

Clear Street

Buy

18.69%

Upside

Reiterated

08/13/25

Clear Street Reaffirms Their Buy Rating on Editas Medicine (EDIT)Reiterate our Buy rating, price target $4, as we continue to view Editas as an overlooked gene editing platform

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

08/12/25

TD Cowen Reaffirms Their Buy Rating on Editas Medicine (EDIT)1:24 AM EDITAS MEDICINE (NASDAQ: EDIT) Buy (1) ESG Target: NA REPORTS Q2; LEAD DEVELOPMENT CANDIDATE BY SEPTEMBER, HUMAN POC DATA BY YE:26 THE TD COWEN INSIGHT EDIT ended Q2:25 with cash of $178.5MM which is expected to fund operations into Q2:27E. EDIT will nominate a lead in vivo gene editing candidate for development by September and anticipates filing an IND by Mid:26 with initial human POC data by YE:26. Remain Buy. EDIT Of A Editas presented multiple preclinical datasets highlighting its in vivo editing technology at ASGCT, TIDES and EHA.

Luca Issi

RBC Capital

Hold

18.69%

Upside

Reiterated

08/12/25

Editas Medicine (EDIT) Receives a Hold from RBC Capital

Mani Foroohar

Leerink Partners

Hold

-70.33%

Downside

Reiterated

03/06/25

Editas Medicine: Hold Rating Maintained Amid Strategic Advancements and Financial Stability

Samantha Semenkow

Citi

Buy

48.37%

Upside

Reiterated

03/06/25

Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position

Geulah Livshits

Chardan Capital

―

Hold

―

Downgraded

12/13/24

Editas Medicine downgraded to Neutral from Buy at ChardanEditas Medicine downgraded to Neutral from Buy at Chardan

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Mitchell Kapoor

H.C. Wainwright

$3→$5

Buy

48.37%

Upside

Reiterated

09/05/25

Joon Lee

Truist Financial

―

Hold

―

Reiterated

09/03/25

Truist Financial Sticks to Their Hold Rating for Editas Medicine (EDIT)

Yanan Zhu

Wells Fargo

$3→$4

Hold

18.69%

Upside

Reiterated

09/03/25

Editas Medicine price target raised to $4 from $3 at Wells FargoEditas Medicine price target raised to $4 from $3 at Wells Fargo

Brian Cheng

J.P. Morgan

―

Sell

―

Reiterated

09/03/25

J.P. Morgan Keeps Their Sell Rating on Editas Medicine (EDIT)

Alec Stranahan

Bank of America Securities

Sell

-70.33%

Downside

Reiterated

09/02/25

Soumit Roy

JonesTrading

―

Hold

―

Reiterated

09/02/25

Jonathan Miller

Evercore ISI

$5→$4

Buy

18.69%

Upside

Initiated

08/22/25

Analysts Are Bullish on These Healthcare Stocks: Editas Medicine (EDIT), Tilray (TLRY)

Gena Wang

Barclays

Hold

-10.98%

Downside

Reiterated

08/13/25

Barclays Sticks to Its Hold Rating for Editas Medicine (EDIT)

Jack Allen

Robert W. Baird

$4→$6

Buy

78.04%

Upside

Reiterated

08/13/25

Editas Medicine price target raised to $6 from $4 at BairdEditas Medicine price target raised to $6 from $4 at Baird

Unknown Analyst

Clear Street

Not Ranked

Clear Street

Buy

18.69%

Upside

Reiterated

08/13/25

Clear Street Reaffirms Their Buy Rating on Editas Medicine (EDIT)Reiterate our Buy rating, price target $4, as we continue to view Editas as an overlooked gene editing platform

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

08/12/25

Luca Issi

RBC Capital

Hold

18.69%

Upside

Reiterated

08/12/25

Editas Medicine (EDIT) Receives a Hold from RBC Capital

Mani Foroohar

Leerink Partners

Hold

-70.33%

Downside

Reiterated

03/06/25

Editas Medicine: Hold Rating Maintained Amid Strategic Advancements and Financial Stability

Samantha Semenkow

Citi

Buy

48.37%

Upside

Reiterated

03/06/25

Buy Rating for Editas Medicine Driven by Promising Preclinical Advances and Strong Financial Position

Geulah Livshits

Chardan Capital

―

Hold

―

Downgraded

12/13/24

Editas Medicine downgraded to Neutral from Buy at ChardanEditas Medicine downgraded to Neutral from Buy at Chardan

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Editas Medicine

1 Month

xxx

Success Rate

3/6 ratings generated profit

Average Return

+1.37%

reiterated a xxx

rating 7 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 50.00% of your transactions generating a profit, with an average return of +1.37% per trade.

3 Months

xxx

Success Rate

8/15 ratings generated profit

Average Return

-0.30%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 53.33% of your transactions generating a profit, with an average return of -0.30% per trade.

1 Year

Phil NadeauTD Cowen

Success Rate

10/15 ratings generated profit

Average Return

+27.13%

reiterated a buy rating 2 months ago

Copying Phil Nadeau's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +27.13% per trade.

2 Years

xxx

Success Rate

10/15 ratings generated profit

Average Return

+48.77%

reiterated a xxx

rating 2 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 66.67% of your transactions generating a profit, with an average return of +48.77% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EDIT Analyst Recommendation Trends

Rating

May 25

Jun 25

Jul 25

Aug 25

Sep 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, EDIT has received 6 Buy Ratings, 18 Hold Ratings, and 2 Sell Ratings. EDIT average Analyst price target in the past 3 months is 3.88.

Each month's total comprises the sum of three months' worth of ratings.

EDIT Financial Forecast

EDIT Earnings Forecast

Next quarter’s earnings estimate for EDIT is -$0.30 with a range of -$0.62 to -$0.04. The previous quarter’s EPS was -$0.63. EDIT beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 48.78% of the time in the same period. In the last calendar year EDIT has Preformed in-line its overall industry.

EDIT Sales Forecast

Next quarter’s sales forecast for EDIT is $4.94M with a range of $500.00K to $25.00M. The previous quarter’s sales results were $3.58M. EDIT beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 59.02% of the time in the same period. In the last calendar year EDIT has Outperformed its overall industry.

EDIT Stock Forecast FAQ

What is EDIT’s average 12-month price target, according to analysts?

Based on analyst ratings, Editas Medicine Inc’s 12-month average price target is 3.88.

What is EDIT’s upside potential, based on the analysts’ average price target?

Editas Medicine Inc has 15.13% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is EDIT a Buy, Sell or Hold?

Editas Medicine Inc has a consensus rating of Hold which is based on 5 buy ratings, 5 hold ratings and 2 sell ratings.

What is Editas Medicine Inc’s price target?

The average price target for Editas Medicine Inc is 3.88. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $6.00 ,the lowest forecast is $1.00. The average price target represents 15.13% Increase from the current price of $3.37.

What do analysts say about Editas Medicine Inc?

Editas Medicine Inc’s analyst rating consensus is a Hold. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of EDIT?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Editas Medicine (EDIT) Stock Forecast & Price Target

EDIT Analyst Ratings

EDIT Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Editas Medicine

EDIT Analyst Recommendation Trends

EDIT Financial Forecast

EDIT Earnings Forecast

EDIT Sales Forecast

EDIT Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts